- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04158193
Acupuncture for Breast Cancer Related Lymphedema
Effectiveness of Acupuncture for Breast Cancer Related Lymphedema Patients: a Multicenter, Randomized, Sham-controlled Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Pan XingFang
- Phone Number: 18649067519
- Email: panxingfang@163.com
Study Contact Backup
- Name: Pan XingFang, Study Principal Investigator
- Phone Number: 18649067519
- Email: panxingfang@163.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 6 months after breast cancer surgery and presents with persistent breast cancer related upper extremity lymphedema for at least 3 months.
- Stage II lymphedema according to the 2016 consensus by the international society of lymphology.
- Women aged 18 to 80 years
- Out-patients
- Estimated life expectancy > 6 months
- Upper extremity lymphedema is defined a more than 10% volume difference between the affected and unaffected arms
Exclusion Criteria:
- Bilateral breast cancer related lymphedema
- Tumor metastasis or recurrent patient
- Patients who is undergoing chemotherapy, radiation therapy or targeted therapy
- Taking diuretic
- Upper extremity lymphedema reached more than 80% volume difference between the affected and unaffected arms
- History of primary lymphedema
- A diagnosis of severe heart, liver, kidney or hematologic disease
- Edema caused by upper extremity disability or other conditions such as heart failure, kidney disease or malnutrition
- Have hypoproteinemia
- Inflammation, scar, or trauma at the site of operation, or other active skin infections
- Unable to self-care, had a history of psychological disorders, or unable to communicate
- Received lymphedema treatment within the past 1 month
- Pregnancy or breastfeeding
- The presence of electronic medical device implants
- Deny to sign the informed written consent, or unwilling to conform to randomization
- Participation in other clinical trials during the study period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Acupuncture group
Subjects in the acupuncture group are given acupuncture treatment.
|
Subjects in acupuncture group will be received acupuncture treatment by inserting LI11, SJ5, SJ9, SJ13, SJ10, HT3, PC2, LI4, and LI15 on the affected limb and RN12, RN9, RN6, RN4, SP9, SP6.
Needles will be remained for 30 minutes each time after DeQi sensation, one time a day,three times a week, the treatment will be lasted for 7 weeks.
|
Experimental: Sham acupuncture control group
Subjects in the sham acupuncture control group are given non-acupoint shallow acupuncture.
|
Subjects in control group will be treated with non-acupoint shallow needling, points will be selected 1 cm at the radial direction from acupoint LI11, SJ5, SJ9, SJ13, SJ10, LI4, HT3, PC2, LI4, LI15; 2 cm at the left of acupoint RN12, RN9, RN6, RN4; 1 cm at the tibial direction from SP9, SP6. The needling manipulation is the same as that of the acupuncture group, but only the superficial skin of points are punctured. The depth of needling is less than 0.5 cm, and no manipulation will be performed after puncturing the skin. Needles will be remained for 30 minutes each time,one time a day,three times a week, the treatment will be lasted for 7 weeks. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Upper extremities volume
Time Frame: 7 weeks
|
Volume measurement is also commonly used for the evaluation of lymphedema and the mean change in inter-limb volume difference from baseline to the end of the 7-week intervention will be included as primary outcome measure.
The volume of the affected and unaffected limb will be measured by the volumetric measuring device (Baseline, America) using the water displacement method, which is considered as the most reliable method for volume measurements.
|
7 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Upper extremities circumferences
Time Frame: 7 weeks
|
Various assessment methods are available but circumference measure is simple, convenient with low cost, and reliable.
Therefore, the primary outcome measures will be the mean change in inter-limb circumference difference from baseline to the end of the 7-week intervention.
The circumference will be measured by the measurement tape (Gulick Attachment, Baseline, America) at the wrist crease,5 cm above the wrist crease,10 cm above the wrist crease,15 cm above the wrist crease,20 cm above the wrist crease,25 cm above the wrist crease,30 cm above the wrist crease,35 cm above the wrist crease,where the lymphedema is most severe and its corresponding location on the unaffected limb.
|
7 weeks
|
VAS distension score
Time Frame: 7 weeks
|
The VAS distension score is used to assess the degree of self-distension feeling at the affected upper extremities.
It is evaluated by drawing a 10 cm horizontal line on the paper.
One end of the horizontal line is 0, indicating no distension feeling; the other end is 10, indicating that the distension is unbearable; the middle part indicates different degrees of swelling.
Let the subject draw a mark on the horizontal line according to the feeling of self-indicating degree of distension.
|
7 weeks
|
Common terminology criteria for adverse events (CTCAE 4.03) - edema limbs criteria
Time Frame: 7 weeks
|
Common terminology criteria for adverse events (CTCAE 4.03) will be used to grade the severity of swelling using the edema limbs criteria.
A grading of mild, moderate or severe swelling will be assessed based on the inter-limb circumference or volume discrepancy, anatomic architecture, appearance, or activities of daily living.
The CTCAE 4.03 will allow us to evaluate the clinical significance of circumference change.
Stages of lymphedema from the international society of lymphology Stages of lymphedema from the international society of lymphology will be used to grade the severity of lymphedema.
Staging of 0, I, II, or III will be assessed based on severity of swelling, ability to reduce swelling by elevation, and skin changes.
|
7 weeks
|
The Disabilities of the Arm, Shoulder and Hand (DASH) Outcome Measure
Time Frame: 7 weeks
|
Disabilities of the arm, shoulder, and hand (DASH) is a scale consists of two concepts: functional status (part A) andsymptoms (part B) respectively.
The functional status part is further divided into three dimensions: physical, social, and psychological.
The total score of the DASH ranges from 0 to 100 with higher scores representing worse symptoms and function.
The DASH has good validity and responsiveness and it is recommended to assess upper extremity function in breast cancer survivors.
The validated Chinese version of the DASH will be used in this study.
|
7 weeks
|
The MOS 36-Item Short-Form Health Survey (SF-36)
Time Frame: 7 weeks
|
The medical outcome study 36-item short-form health survey (SF-36) is a commonly used instrument to assess quality of life that has good validity.
The SF-36 includes the following eight concepts: physical functioning, role limitations due to physical problems, social functioning, bodily pain, general mental health, role limitations due to emotional problems, vitality, and general health perception.
The validated Chinese version of the SF-36 will be used in this study.
|
7 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014CB543202-03
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Lymphedema
-
Odense University HospitalZealand University Hospital; Vejle Hospital; Herlev and Gentofte HospitalRecruitingLymphedema | Breast Cancer Lymphedema | Lymphedema, Breast Cancer | Lymphedema of Upper Limb | Lymphedema, Secondary | Lymphedema Arm | Lymphedema; SurgicalDenmark
-
Koya Medical, Inc.RecruitingLymphedema | Lymphedema, Breast Cancer | Lymphedema ArmUnited States
-
Hacettepe UniversityCompletedLymphedema, Breast CancerTurkey
-
Odense University HospitalDanish Cancer SocietyActive, not recruitingPathologic Processes | Neoplasms | Skin Diseases | Lymphatic Diseases | Postoperative Complications | Breast Cancer | Breast Diseases | Lymphedema | Breast Neoplasm | Surgery | Secondary Lymphedema | Breast Cancer Lymphedema | Lymphedema, Breast Cancer | Lymphedema of Upper Limb | Lymphedema Arm | Iatrogenic Lymphedema | A... and other conditionsDenmark
-
Koya Medical, Inc.RecruitingLymphedema | Lymphedema of Upper Arm | Lymphedema, Breast CancerUnited States
-
Instituto Nacional de Cancer, BrazilRecruitingBreast Neoplasms | Lymphedema of Upper Arm | Breast Cancer Related Lymphedema | Lymphedema, SecondaryBrazil
-
Instituto Nacional de Cancer, BrazilCompletedBreast Neoplasms | Lymphedema of Upper Arm | Breast Cancer Related Lymphedema | Lymphedema, SecondaryBrazil
-
University Hospital, Basel, SwitzerlandSwiss National Science Foundation; Krebsforschung Schweiz, Bern, Switzerland; Rising Tide FoundationRecruitingLymphedema, Breast CancerSpain, Switzerland, United States, Germany, Argentina, Austria, Belgium, Brazil, Canada, Greece, Italy, Netherlands, Romania, Sweden
-
Massachusetts General HospitalHeinz Family FoundationRecruitingBreast Cancer | Lymphedema | Edema | Lymphedema of Upper Arm | Breast Cancer Lymphedema | Breast Cancer Metastatic | Lymphedema of Upper Limb | Breast Cancer Stage | Lymphedema Arm | Edema Arm | Lymphedema of the HandsUnited States
-
Izmir Bakircay UniversityBezmialem Vakif University; Istanbul Kent UniversityCompletedLymphedema, Breast Cancer | Lymphedema of Upper LimbTurkey
Clinical Trials on acupuncture
-
Federal University of São PauloCompleted
-
University of ZurichCharite University, Berlin, Germany; First Teaching Hospital of Tianjin University...CompletedExperimental Dental PainSwitzerland
-
University of SkövdeCompleted
-
National Research Centre of Complementary and Alternative...Norwegian Acupuncture CollegeUnknown
-
Chengdu University of Traditional Chinese MedicineChongqing Medical University; Hunan University of Traditional Chinese MedicineCompletedFunctional Dyspepsia | Postprandial Distress SyndromeChina
-
Chang Gung Memorial HospitalRecruitingIntracranial HemorrhagesTaiwan
-
University of MichiganMassachusetts General Hospital; National Center for Complementary and Integrative...Completed
-
University Medicine GreifswaldRecruitingGagging During Transesophageal EchocardiographyGermany
-
Huazhong University of Science and TechnologyThe University of Hong Kong; Heilongjiang University of Chinese Medicine; Hubei...CompletedPolycystic Ovary SyndromeChina
-
China Medical University HospitalNot yet recruiting